Using various NSCLC cell lines with different KRAS mutational status and adapting KrasLA2 mouse model, we then demonstrated the effectiveness of KYA1797K, which destabilizes Ras via inhibition of the Wnt/β-catenin pathway, in erlotinib-resistant KRAS mutant NSCLC in vitro and in vivo. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.